PRME:NSD-Prime Medicine, Inc. Common Stock (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 3.43

Change

-0.02 (-0.58)%

Market Cap

N/A

Volume

3.04M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-7.62 (-1.62%)

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

-6.64 (-0.63%)

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

-4.51 (-1.63%)

USD 35.44B
ARGX argenx NV ADR

+2.72 (+0.50%)

USD 32.73B
MRNA Moderna Inc

-0.77 (-1.20%)

USD 25.27B
BGNE BeiGene Ltd

+2.62 (+1.13%)

USD 24.38B
RPRX Royalty Pharma Plc

-0.14 (-0.49%)

USD 16.72B
UTHR United Therapeutics Corporatio..

-5.36 (-1.50%)

USD 15.95B
SMMT Summit Therapeutics PLC

-0.56 (-2.79%)

USD 15.35B
PCVX Vaxcyte Inc

-1.29 (-1.12%)

USD 14.00B

ETFs Containing PRME

XDNA 5.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -61.29% 21% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.29% 21% F 12% F
Trailing 12 Months  
Capital Gain -60.57% 24% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.57% 24% F 13% F
Trailing 5 Years  
Capital Gain -83.04% 37% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -83.04% 37% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain -20.00% N/A N/A 17% F
Dividend Return -20.00% N/A N/A 17% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 25.08% N/A N/A 69% C-
Risk Adjusted Return -79.75% N/A N/A 10% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector